(PAHC) Phibro Animal Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71742Q1067
PAHC: Vaccines, Minerals, Antibiotics, Performance Products
Phibro Animal Health Corporation (NASDAQ:PAHC) is a global leader in animal health and mineral nutrition, operating across the U.S., Israel, Brazil, Ireland, and other international markets. The company is structured into three core segments: Animal Health, Mineral Nutrition, and Performance Products. Its diverse product portfolio caters to both food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
The Animal Health segment offers a range of solutions such as antibacterials, anticoccidials, nutritional specialties, and vaccines. These products are designed to enhance animal health, ensure food safety, and improve overall animal welfare. Additionally, Phibro develops and markets microbial and bioproducts for various applications, serving customers in animal health, nutrition, environmental, industrial, and agricultural sectors.
In the Mineral Nutrition segment, the company specializes in trace minerals like zinc, manganese, copper, and iron. These are formulated to meet the dietary needs of livestock, ensuring optimal nutrient balance. Phibro also provides specialty ingredients for personal care, industrial chemicals, and catalyst industries, demonstrating its versatility beyond animal health.
Phibro’s products are distributed through a network of local sales offices, targeting integrated poultry, swine, and cattle producers, as well as commercial animal feed manufacturers, wholesalers, and distributors. The company, originally known as Philipp Brothers Chemicals, Inc., rebranded to Phibro Animal Health Corporation in 2003 and has been operational since 1946, with its headquarters in Teaneck, New Jersey.
Financially, Phibro has a market capitalization of approximately $1.02 billion, with a trailing P/E ratio of 52.48 and a forward P/E of 10.57. The price-to-book ratio stands at 4.04, and the price-to-sales ratio is 0.97. These metrics provide insight into the company’s valuation for investors and fund managers considering its position in the market.
Additional Sources for PAHC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PAHC Stock Overview
Market Cap in USD | 958m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2014-04-11 |
PAHC Stock Ratings
Growth 5y | 20.1% |
Fundamental | -1.13% |
Dividend | 39.2% |
Rel. Strength Industry | 78.3 |
Analysts | 2.4/5 |
Fair Price Momentum | 21.89 USD |
Fair Price DCF | 17.41 USD |
PAHC Dividends
Dividend Yield 12m | 1.72% |
Yield on Cost 5y | 2.32% |
Annual Growth 5y | 0.00% |
Payout Consistency | 97.1% |
PAHC Growth Ratios
Growth Correlation 3m | 43.7% |
Growth Correlation 12m | 84.6% |
Growth Correlation 5y | -27.2% |
CAGR 5y | 6.51% |
CAGR/Max DD 5y | 0.10 |
Sharpe Ratio 12m | -0.08 |
Alpha | 68.26 |
Beta | 1.14 |
Volatility | 42.41% |
Current Volume | 335.6k |
Average Volume 20d | 350.6k |
As of March 15, 2025, the stock is trading at USD 21.25 with a total of 335,608 shares traded.
Over the past week, the price has changed by -10.11%, over one month by -17.13%, over three months by -5.67% and over the past year by +79.87%.
Neither. Based on ValueRay Fundamental Analyses, Phibro Animal Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -1.13 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PAHC as of March 2025 is 21.89. This means that PAHC is currently overvalued and has a potential downside of 3.01%.
Phibro Animal Health has received a consensus analysts rating of 2.40. Therefor, it is recommend to sell PAHC.
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 3
- Strong Sell: 0
According to ValueRays Forecast Model, PAHC Phibro Animal Health will be worth about 23.6 in March 2026. The stock is currently trading at 21.25. This means that the stock has a potential upside of +11.25%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 21 | -1.2% |
Analysts Target Price | 19.4 | -8.7% |
ValueRay Target Price | 23.6 | 11.2% |